Abstract
Introduction
In the context of the genetic studies on breast cancer, the molecular classification became the main topic of conversation and the breast tumors are classified into molecular subtypes:
Luminal A and B (recently a third group as C group is considered to be added), HER-2 Like, Basal Like and unclassified [1] . The amplification and overexpression of HER-2 oncogen was known to be an important prognostic factor for breast cancer [2] . It was shown in the studies that, HER2 Like and Basal Like groups have worse prognosis than other groups [3, 4] . HER -2 oncogen, also known as CerbB2 is a member of epidermal growth factor receptor (EGFR) family [5] [6] [7] . It's located on chromosome 17q21 and plays a role in cell growth, differentiation, adhesion and motility, signal conduction [8] . The expression in breast cancer gives tumor aggressive characteristics. The importance of HER 2 oncogen is mentioned above and, HER 2 receptor determination in breast cancer patients is a very important milestone for the determination of the prognosis and treatment modalities. CerbB2 positive tumors had poor prognosis. However the introduction of the anti-tumor agents that target this receptor and pathway have changed the poor prognosis of this tumor group as adjuvant or metastatic context [9] [10] [11] [12] . Several methods were tested for HER 2 receptor determination. However two of them are used more common worldwide: Immunohistochemical staining and fluorescence in situ hybridization (FISH) methods [13] [14] . The score for immunohistochemical method and their meanings are provided at is still no consensus on which method is the most predictive and useful [13] . FISH that accepted in the literature and practice was considered as the gold standard test for immunohistochemically CerbB2 (++) tumors [13] [14] [15] [16] [17] [18] [19] . Breast tumors are divided into 4 groups according to the scores of CerbB2 receptor: 0 (negative), 1(+), 2(+) and 3(+). Practically, the prognostic features are considered as similar for each group. CerbB2 (++) tumors are divided into 2 groups by FISH and therefore, prognosis needs to be re-evaluated for these subgroups (FISH(+) and FISH(-) ). The aim of our study is to compare FISH(+) and FISH(-) groups determined by the FISH test in terms of relaps duration in the CerbB2 (++) non-metastatic breast cancer patient group.
Material and Methods
Total of 85 patients from The Kayseri Research and Training Hospital in Kayseri, Kayseri
Erciyes University Hospital and Mersin State Hospital were included in this study. These patients were in the adjuvant context during diagnosis, and their CerbB2 results were found to be immunohistochemically (++). The time to relaps were evaluated for the patients. They were entered into the SPSS 16.0 statistical software and Kaplan Meier was used.
Results
Total of 85 patients were evaluated. The number of FISH(+) cases were 37 and FISH(-) cases were 48. HER-2 score was shown in table 1. The prognostic factors of the patients were provided at [20] [21] [22] [23] [24] [25] . In our study, percentage of positive FISH cases was 43.5%.
The most important reason to use FISH in Cerb B2 receptor IHC(2+) cases is to determine the prognosis and to modify the treatment modalities. As is known, Cerb B2 (3+) cases benefit from trastuzumab at the adjuvant or metastatic step, lapatinib-based regimes at the metastatic step. However Cerb B2 (2+) and Cerb B2 (3+) cases were identified as separate groups at IHC evaluation. So, should all Cerb B2 (2+) cases be considered as proper for "anti-HER2
receptor treatment"? Do CerB B2 IHC (2+) cases, even if they are FISH(+), give response to anti-receptor treatment as IHC(3+) cases.
At the end of our study, DFS was calculated as mean and median for FISH(+) and FISH(-)
groups. In the analysis of progression-free survival, the mean DFS was 46±5 and 73±8 months for FISH(+) and FISH(-) groups. However, the median DFS was 38±9 months for the FISH positive group. No median PFS was found for FISH (-) group.
According to this analysis, even though the cases are IHC(2+), i.e. in the same group, they are divided into 2 groups prognostically, and these two groups are determined by FISH test. No significant difference in the age, stage, menopausal status, ER and PR receptor status, grade and adjuvant chemotherapy regimes was found between groups. This finding suggests that, the most important and the only factor in the formation of two separate groups is the FISH result.
In HERA study, CerbB2 (2+) FISH(+) cases were evaluated in two groups. Local CerbB2 (2+) FISH(+) cases benefited from adjuvant herceptin treatment significantly, however central CerbB2(2+) FISH(+) cases didn't. No significant difference was found in the combination of two groups [9] . Again, for CerbB2 (2+) FISH(+) cases in the adjuvant studies, significant difference was found for DFS in NSABP B31 study, and was not found in NCCTG N9831 study [10] [11] .
Conclusion
The percentage of FISH positivity ranged from 0% to 20% for Cerb B2 IHC(0+) cases and from 3.1% to 50. 0% for Cerb B2 IHC (1+) in the studies [20] [21] [22] [23] [24] [25] . The percentage of FISH negativity ranged from 6.2% to 23.5% for Cerb B2 IHC(3+) cases [20] [21] [22] [23] [24] [25] . Therefore we 
